Tumor Biology

, Volume 36, Issue 7, pp 5149–5156 | Cite as

Correlation between TGF-β1 gene 29 T > C single nucleotide polymorphism and clinicopathological characteristics of osteosarcoma

  • Yang Wu
  • Jinmin Zhao
  • Maolin He
Research Article


Transforming growth factor (TGF)-β1 is the most abundant growth factor in human bone. Several polymorphisms have been described in the TGF-β1 gene. To explore the correlation between TGF-β1 gene single nucleotide polymorphism and the clinicopathological characteristics of osteosarcoma. TaqMAN PCR technique was used to detect the TGF-β1 gene polymorphism of 124 patients with osteosarcoma from last follow-up and 136 healthy controls. The difference of gender, age, and allele frequency between patient group and control group with χ 2 text were tested. The relationship between single nucleotide polymorphism and the risk of osteosarcoma with logistic regression and different survival rates of different genotypic patients with osteosarcoma through Kaplan-Meier were analyzed. There is no remarkable difference of the three genotypes in TGF-β1 gene 509C > T locus between the patient group and control group (P = 0.26). However, there are significant distributive differences in 29 T > C genotype (P = 0.04), which shows that patients carrying TT genotype have more risk to get osteosarcoma than patients carrying CC genotype (odds ratio (OR) = 2.10, 95 % confidence interval (CI) = 1.08–4.05). The percentage of T allele frequency of patient group, as 60.1 %, is larger than the control group, as 48.9 %. By comparing with patients carrying CC genotype, patients carrying TT genotype have two times risk of metastasis (OR = 2.30, 95 % CI = 1.05–5.06), and most of them are in the period of Enneking IIB (OR = 2.54, 95 % CI = 1.18–5.51). The survival analysis indicates that there is no any significant decrease when there is recurrence in patients carrying TT genotype. The morbidity and metastasis of osteosarcoma are relevant to TGF-β1 gene 29 T > C single nucleotide polymorphism.


Osteosarcoma Single nucleotide polymorphism TGF-β1 Clinicopathological characteristics 



This research was supported by the Guangxi Innovative Program of Graduate Education (Grant No. YCSZ2013035).

Conflict of interest



  1. 1.
    Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013;137(1):89–99.CrossRefPubMedGoogle Scholar
  2. 2.
    Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 2009;27(4):557–65.CrossRefPubMedGoogle Scholar
  4. 4.
    Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 2009;152:467–78.CrossRefPubMedGoogle Scholar
  5. 5.
    Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, et al. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 1985;316(6030):701–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Mantel PY, Schmidt-Weber CB. Transforming growth factor-beta: recent advances on its role in immune tolerance. Methods Mol Biol. 2011;677:303–38.CrossRefPubMedGoogle Scholar
  7. 7.
    Kloen P, Gebhardt MC, Perez-Atayde A, Rosenberg AE, Springfield DS, Gold LI, et al. Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression. Cancer. 1997;80(12):2230–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Franchi A, Arganini L, Baroni G, Calzolari A, Capanna R, Campanacci D, et al. Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high-grade osteosarcomas. J Pathol. 1998;185(3):284–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Amirghofran Z, Jalali SA, Ghaderi A, Hosseini SV. Genetic polymorphism in the transforming growth factor beta1 gene (-509 C/T and -800 G/A) and colorectal cancer. Cancer Genet Cytogenet. 2009;190(1):21–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Minamiya Y, Miura M, Hinai Y, Saito H, Ito M, Ono T, et al. Transforming growth factor-beta1 29 T > C genetic polymorphism is associated with lymph node metastasis in patients with adenocarcinoma of the lung. Tumour Biol. 2010;31(5):437–41.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang Y, Chu X, Meng X, Zou F. Association of TGF-beta1–509C/T polymorphisms with breast cancer risk: evidence from an updated meta-analysis. Tumour Biol. 2014;35(2):935–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet. 1999;8(1):93–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Silverman ES, Palmer LJ, Subramaniam V, Hallock A, Mathew S, Vallone J, et al. Transforming growth factor-beta1 promoter polymorphism C-509 T is associated with asthma. Am J Respir Crit Care Med. 2004;169(2):214–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Yamada Y, Miyauchi A, Takagi Y, Tanaka M, Mizuno M, Harada A. Association of the C-509-- > T polymorphism, alone of in combination with the T869-- > C polymorphism, of the transforming growth factor-beta1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women. J Mol Med (Berl). 2001;79(2-3):149–56.CrossRefGoogle Scholar
  15. 15.
    Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. Bone. 2003;32(3):297–310.CrossRefPubMedGoogle Scholar
  16. 16.
    Xu S, Yang S, Sun G, Huang W. Zhang Y. DNA Cell Biol: Transforming growth factor-beta polymorphisms and serum level in the development of osteosarcoma; 2014.Google Scholar
  17. 17.
    Schedlich LJ, Yenson VM, Baxter RC. TGF-beta-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells. Mol Cell Endocrinol. 2013;377(1–2):56–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF. A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone. 1997;20(3):289–94.CrossRefPubMedGoogle Scholar
  19. 19.
    Langdahl BL, Uitterlinden AG, Ralston SH, Trikalinos TA, Balcells S, Brandi ML, et al. Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. Bone. 2008;42(5):969–81.CrossRefPubMedGoogle Scholar
  20. 20.
    Tang RG, Huang YZ, Yao LM, Xiao J, Lu C, Yu Q. Polymorphisms of transforming growth factor beta 1 (RS#1800468 and RS#1800471) and esophageal squamous cell carcinoma among Zhuangese population, China. Gene. 2013;512(1):1–5.Google Scholar
  21. 21.
    Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(5):759–64.PubMedGoogle Scholar
  22. 22.
    Shu XO, Gao YT, Cai Q, Pierce L, Cai H, Ruan ZX, et al. Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res. 2004;64(3):836–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Saha A, Gupta V, Bairwa NK, Malhotra D, Bamezai R. Transforming growth factor-beta1 genotype in sporadic breast cancer patients from India: status of enhancer, promoter, 5′-untranslated-region and exon-1 polymorphisms. Eur J Immunogenet. 2004;31(1):37–42.CrossRefPubMedGoogle Scholar
  24. 24.
    Rajkumar T, Samson M, Rama R, Sridevi V, Mahji U, Swaminathan R, et al. TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat. 2008;112(1):81–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Joshi NN, Kale MD, Hake SS, Kannan S. Transforming growth factor beta signaling pathway associated gene polymorphisms may explain lower breast cancer risk in western Indian women. PLoS One. 2011;6(8):e21866.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Zhang HY, Wang ZQ, Li YY, Wang F, Zeng QR, Gao Y, et al. Transforming growth factor-beta1-induced epithelial-mesenchymal transition in human esophageal squamous cell carcinoma via the PTEN/PI3K signaling pathway. Oncol Rep. 2014.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Orthopedic Trauma and Hand SurgeryThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
  2. 2.Division of Spinal Surgery, Research Center for Regenerative MedicineThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
  3. 3.Department of Orthopedic Trauma and Hand Surgery, Research Center for Regenerative MedicineThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina

Personalised recommendations